Status:
COMPLETED
Effect of Prime Solution on Fluid Balance After Open Heart Surgery
Lead Sponsor:
University of Helsinki
Collaborating Sponsors:
B. Braun Melsungen AG
Conditions:
Valve Surgery
Coronary Artery Bypass Grafting
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The use of Tetraspan® as prime solution can reduce fluid extravasation after perfusion versus Ringer acetate. Plasma-adapted HES-solutions produce also less acidosis.
Detailed Description
Fifty patients scheduled for elective primary and single cardiac surgery include in this prospective study. Patients with preoperative coagulation disorders, or renal or hepatic failure, are excluded....
Eligibility Criteria
Inclusion
- Elective combined cardiac surgery
Exclusion
- Liver failure
- Kidney failure
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00797589
Start Date
January 1 2009
End Date
September 1 2012
Last Update
August 25 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital
Helsinki, Finland, 00029